Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis
Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis
复制标题
DOI：
10.1681/asn.2014020212
复制
发表时间：
2015-02-01
影响因子：
13.6
通讯作者：
Dwyer, Jamie P.
中科院分区：
文献类型：
--
作者：
Lewis, Julia B.;Sika, Mohammed;Dwyer, Jamie P.
透析患者需要磷结合剂来预防高磷血症，并且缺铁。我们研究了柠檬酸铁作为磷结合剂和铁源。在这项序贯、随机化试验中，441例接受透析的受试者在52周的活性对照期内随机接受柠檬酸铁或活性对照，随后是4周的安慰剂对照期，其中完成活性对照期的柠檬酸铁受试者重新随机接受柠檬酸铁或安慰剂。主要分析比较了安慰剂对照期间柠檬酸铁和安慰剂之间磷的平均变化。序贯把关策略控制了血清铁蛋白、转铁蛋白饱和度和静脉铁剂和促红细胞生成素刺激剂使用的研究1型错误，作为活性对照期间预先规定的次要结局。与安慰剂相比，柠檬酸铁控制了磷，平均治疗差异为-2.2 +/- 0.2 mg/dl（平均值+/- SEM）（P
Patients on dialysis require phosphorus binders to prevent hyperphosphatemia and are iron deficient. We studied ferric citrate as a phosphorus binder and iron source. In this sequential, randomized trial, 441 subjects on dialysis were randomized to ferric citrate or active control in a 52-week active control period followed by a 4-week placebo control period, in which subjects on ferric citrate who completed the active control period were rerandomized to ferric citrate or placebo. The primary analysis compared the mean change in phosphorus between ferric citrate and placebo during the placebo control period. A sequential gatekeeping strategy controlled study-wise type 1 error for serum ferritin, transferrin saturation, and intravenous iron and erythropoietin-stimulating agent usage as prespecified secondary outcomes in the active control period. Ferric citrate controlled phosphorus compared with placebo, with a mean treatment difference of -2.2 +/- 0.2 mg/dl (mean +/- SEM) (P